secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orgenesis Inc. (—)
CIK:        0001460602
Form:       8-K
Filed at:   2024-07-12T23:59:59+00:00
Accession:  0001493152-24-027083
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orgenesis acquires Theracell assets including TIL platform and 100% of Theracell IKE for $13M less $10.3M debt
--------------------------------------------------------------------------------

- Orgenesis to acquire 50% of Theracell IKE (to own 100%) plus five product platforms from Theracell for $13M valuation minus $10,324,241.79 debt.
- Net consideration ~$2.7M; paid $400k in 60 days, $250k in 1 year, remainder in four annual installments starting Dec 30, 2025.
- Products acquired include TIL manufacturing, 3rd-gen GMP lentivirus process, oncolytic virus cell carrier, MSC therapy for kidney, and transdermal delivery platform.
- Theracell owes Orgenesis $10.3M, effectively used as credit toward purchase price; Theracell indemnifies Orgenesis for pre-closing liabilities.
- Transaction closed July 12, 2024; Orgenesis gains intellectual property and ownership of Theracell IKE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1460602/000149315224027083/0001493152-24-027083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1460602/000149315224027083/from8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-027083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer